StreetAlpha.app
Home › Stocks › EOLS

Evolus, Inc. (EOLS)

Healthcare
$6.69
▲ +0.90%
LAST CLOSE · NOV 17

Evolus sells Jeuveau and Evolysse injectable aesthetic treatments to licensed aesthetic practitioners. It last closed at $6.69 on Nov 17, up 0.90% on the day. The average 12-month price target from 2 analysts is $14.00 (+109.3% from the last close), with a high of $15.00 and a low of $13.00.

AI Auto Pilots
Is EOLS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$325.5M
+13.9% vs a year ago
Net income
−$31.1M
−9.6% margin
EPS (diluted)
−$0.48
Free cash flow
−$4.9M
−1.5% margin
Valuation
Market cap
$442.8M
66.2M shares
P/E
–
No P/E while losing money
Price to sales
1.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.7M
At Sep 30
Debt
$156.9M
At Sep 30
Shareholder equity
−$37.8M
Shares outstanding
66.2M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $99.7M$99.7MFY2021FY2022: $148.6M$148.6MFY2022FY2023: $202.1M$202.1MFY2023FY2024: $266.3M$266.3MFY2024FY2025: $297.2M$297.2MFY2025

From EOLS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated EOLS in the past 90 days, not enough for a consensus
Average 12-month target
$14.00
▲ 109.3% upside

Based on 2 analysts who set a price target on EOLS in the past 90 days. The average target is $14.00, with a high of $15.00 and a low of $13.00, compared with the last close of $6.69.

Low $13.00Avg $14.00High $15.00
Blue marker: last close $6.69
Highest target$15.00
Average target$14.00
Lowest target$13.00
Latest rating changes
BTIGTarget raised
Nov 5Buy$13 → $15
HC Wainwright & Co.Reiterated
Aug 25Buy$13
BTIGReiterated
Jun 17Buy$13
DateFirmActionRatingPrice target
Nov 5BTIGTarget raisedBuy$13 → $15
Aug 25HC Wainwright & Co.ReiteratedBuy$13
Jun 17BTIGReiteratedBuy$13
Loading…

Technical Analysis

EOLS · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 7% below its 20 day and 12% below its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot at $6.57, and the nearest resistance the swing high (May 28) at $6.76.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 6.1%/day
Key levels
$9.3152 week high+39.2%
$7.5250 day average+12.4%
$7.41100 day average+10.8%
$7.1620 day average+7.0%
$6.85Pivot R1+2.4%
$6.76Swing high (May 28)+1.0%
$6.69Last close
$6.57Pivot−1.8%
$6.47Swing low (Jun 11)−3.3%
$6.42Pivot S1−4.0%
$6.39200 day average−4.5%
$3.8652 week low−42.3%
Indicators
RSI (14)41.01Middle of its rangeNeutral
MACD-0.20Below its signal lineBearish
Stochastic26.5Middle of its rangeNeutral
ADX (14)14.8No clear trend
Williams %R-74.5Oversold below −80, overbought above −20Neutral
CCI (20)-151.0Oversold below −100, overbought above 100Oversold
Rate of change−9.2%Change over 10 sessionsBearish
ATR (14)$0.41Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for EOLS

What happened before

See how EOLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EOLS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EOLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in EOLS in the last 90 days.

Loading…

See today’s whale options flow across the market →

EOLS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●82 buying vs 74 selling
  • ▼Held by funds -7.2 pts
  • ▲Funds holding +12
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding170158+7.6%
In funds' top 10220.0%
Held by funds76.6%83.8%−7.2 pts
New / increased31 / 5132 / 56−6.8%
Reduced / sold out54 / 2038 / 21+25.4%
Put/call ratio0.010.28−97.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EOLS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EOLS is in one of them and how their past EOLS trades turned out.

EOLS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EOLS in an article yet. Here's the latest on the wider market.

About Evolus

Evolus is a medical aesthetics company based in Newport Beach, California. It sells Jeuveau, an injectable botulinum toxin used to smooth frown lines, and Evolysse, a line of injectable hyaluronic acid gels used for wrinkles, folds, and facial volume. Its customers are licensed aesthetic practitioners, and patients generally pay for these treatments directly out of pocket rather than through insurance. The company relies on outside manufacturers in South Korea and France to produce its products.

Headquarters
Newport Beach, CA